Metsera Inc.’s (NASDAQ:MTSR) Lock-Up Period Will Expire Tomorrow

Posted by Danessa Lincoln on Jul 29th, 2025

Metsera’s (NASDAQ:MTSR – Get Free Report) lock-up period is set to end on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analysts Set New Price Targets

A number of equities analysts have commented on MTSR shares. Wells Fargo & Company began coverage on shares of Metsera in a research note on Friday, June 20th. They issued an “overweight” rating and a $65.00 target price on the stock. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Metsera has an average rating of “Buy” and a consensus target price of $55.00.

Check Out Our Latest Stock Report on MTSR

Metsera Stock Performance

Shares of Metsera stock opened at $39.43 on Tuesday. The company’s fifty day moving average price is $32.05. Metsera has a 12 month low of $12.30 and a 12 month high of $47.40.

Metsera (NASDAQ:MTSR – Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Hedge Funds Weigh In On Metsera

Several institutional investors have recently bought and sold shares of MTSR. Strs Ohio purchased a new stake in Metsera during the first quarter worth $76,000. KLP Kapitalforvaltning AS bought a new position in shares of Metsera in the 2nd quarter worth $122,000. New York State Common Retirement Fund purchased a new stake in shares of Metsera during the 1st quarter worth $131,000. Corebridge Financial Inc. purchased a new stake in shares of Metsera during the 1st quarter worth $206,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Metsera during the first quarter valued at about $248,000.

About Metsera

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.